In August, the Federal Circuit affirmed the PTAB on every issue
in 9 (81.82%) cases on appeal from post-grant proceedings,
including in four precedential opinions: Axonics, Inc. v.
Medtronic, Inc. (Case No. 22-1532), Rembrandt Diagnostics,
LP v. Alere, Inc. (No. 21-1796), Incept LLC v. Palette
Life Sciences, Inc. (No. 21-2063), and Volvo Penta of the
Americas, LLC v. Brunswick Corp. (No. 22-1765). The Federal
Circuit issued a mixed outcome in 2 (18.18%) appeals, and did not
issue any opinions reversing or vacating every issue or dismissing
any appeals, which may occur, for example, when the Federal Circuit
determines that it does not have jurisdiction over an appeal.

Through August 31, 2023, the Federal Circuit cumulatively
decided 1,195 appeals from the PTAB in IPRs, CBMs, and PGRs. While
the vast majority of these appeals came from IPR proceedings, the
number of PGR appeals has slowly increased over time.